[12] Patent
[11] Patent No.:GC0007598  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126083
Date of the Decision to Grant the Patent:16/Apr/2018

[21] Application No.:GC 2010-17251

[22] Filing Date:7/12/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
EP
10/12/2009
19/8/2010
09015310.7
10173407.7

[72] Inventors:1- Nikolaos Dimoudis،2- Georg Fertig،3- Alexander Fidler،4- Klaus Kaluza،5- Martin Lanzendoerfer،6- Marlene Pickl،7- Carola Ries،8- Stefan Seeber

[73] Owner: F. Hoffmann-La Roche AG, 124 Grenzacherstrasse, CH-4070, Basel, Switzerland

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: C07K 16/28; A61K 39/00 (2006.01)

[56] Cited Documents:

-WO 2009/112245 A1 (TRANSGENE SA.) 17 September 2009
-WO 2009/026303 A1 (AMGEN mo.) 26 February 2009
 
Examiner: PH. Neda J. AlMuallem

[54] ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
[57] Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
No. of claims: 22     No. of figures: 4


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.